The utility of presurgical CA125 to predict optimal tumor cytoreduction of epithelial ovarian cancer

International Journal of Gynecological Cancer

Volumn 16, Issue 2, 2006, Pages 496-500

  Barlow, T S ^a   Przybylski, M ^a   Schilder, J M ^a   Moore, D H ^a   Look, K Y ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

CA125; Ovarian cancer; Surgical debulking

Indexed keywords

CA 125 ANTIGEN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; ASCITES; CANCER ADJUVANT THERAPY; CANCER STAGING; COMPUTER PROGRAM; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; FEMALE; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; OVARY CANCER; PREDICTION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; RELIABILITY; ROC CURVE; SENSITIVITY AND SPECIFICITY;

ADENOCARCINOMA; ADENOCARCINOMA, CLEAR CELL; ADENOCARCINOMA, MUCINOUS; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CA-125 ANTIGEN; CHEMOTHERAPY, ADJUVANT; CYSTADENOCARCINOMA, PAPILLARY; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; REGISTRIES; ROC CURVE; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 33646059529     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2006.00573.x     Document Type: Article

References (23)

1. McGuire WP Hoskins WJ Brady MF et al Cyclophosphamide and cisplatin versus paclitaxel and cisplatin: a phase III randomized trial in patients with suboptimal stage III/IV ovarian cancer N Engl J Med 1999 334 1 6
2. Piccart MJ Bertelsen K James K et al Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women in advanced epithelial ovarian cancer: three year results J Natl Cancer Inst 2000 92 699 708
3. Hoskins WJ McGuire WP Brady MF et al The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma Am J Obstet Gynecol 1994 170 974 9
4. Griffiths CT Parker LM Fuller AF Role of cytoreductive surgery treatment in the management of advanced ovarian cancer Cancer Treat Rep 1979 63 235 40
5. Omura GA Brady MF Homesley HD et al Long-term follow up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience J Clin Oncol 1991 9 1138 50
6. Rubin SC Wong GY Curtin JP Barakat RR Hakes TB Hoskins WJ Platinum based chemotherapy of high risk stage I epithelial ovarian cancer following comprehensive surgical staging Obstet Gynecol 1993 82 143 7
7. Mayer AR Chambers SK Graves E et al Ovarian cancer staging: does it require a gynecologic oncologist? Gynecol Oncol 1992 47 223 7
8. Eisenkop SM Spirtos NM Montag TW Nalick RH Wang HJ The impact of subspecialty training on the management of advanced ovarian cancer Gynecol Oncol 1992 47 203 9
9. Bristow RE Tomacruz RS Armstrong DK Trimble EL Montz FJ Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis J Clin Oncol 2002 20 1248 59
10. Barnholtz-Sloan JS Schwartz AG Munkarah AR et al Ovarian cancer: changes in patterns at diagnosis and relative survival over the last three decades Am J Obstet Gynecol 2003 189 1120 7
11. Jemal A Tiwari RC Murray T et al Cancer statistics CA Cancer J Clin 2004 54 8 29
12. Mazzeo F Berliere M Kerger J et al Neoadjuvant chemotherapy followed by surgery and adjuvant chemotherapy in patients with primarily unresectable advanced ovarian cancer Gynecol Oncol 2003 90 163 9
13. Schwartz PE Rutherford TJ Chambers JT Kohorn EI Thiel RP Neoadjuvant chemotherapy for advanced ovarian cancer: long-term survival Gynecol Oncol 1999 72 93 9
14. Vergote I De Wever I Tjalma W Van Gamberen M Decloedt J Van Dam P Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian cancer: a retrospective analysis of 285 patients Gynecol Oncol 1998 71 431 6
15. Byrom J Widjaja E Redman CWE Jones PW Tebby S Can pre-operative computed tomography predict resectability of ovarian carcinoma at primary laparotomy? BJOG 2002 109 369 75
16. Bristow RE Duska LR Lambrou NC et al A model for predicting surgical outcome in patients with advanced ovarian carcinoma using computed tomography Cancer 2000 89 1532 40
17. Chi DS Venkatraman ES Masson V Hoskins WJ The ability of preoperative serum CA-125 to predict optimal primary tumor cytoreduction in stage III epithelial ovarian carcinoma Gynecol Oncol 2000 77 227 31
18. Memarzadeh Lee SB Berek JS Farias-Eisner R CA-125 levels are a weak predictor of optimally cytoredcutive surgery in patients with advance epithelial ovarian cancer Int J Gynecol Cancer 2003 13 120 4
19. Cooper BC Sood AK Davis CS et al Preoperative CA-125 levels: an independent prognostic factor for epithelial ovarian cancer Obstet Gynecol 2002 100 59 64
20. Brockbank EC Ind TEJ Barton DPJ et al Preoperative predictors of suboptimal cytoreduction in women with clinical evidence of advance primary epithelial ovarian cancer Int J Gynecol Cancer 2004 14 42 50
21. Punglia RS D'Amico AV Catalona WJ Roehl KA Kuntz KM Effect of verification bias on screening for prostate cancer by measurement of prostate specific antigen N Engl J Med 2003 349 335 42
22. Vergote IB Neoadjuvant chemotherapy in advanced ovarian cancer. American Society of Clinical Oncology 2004 Educational Book Alexandria, VA American Society of Clinical Oncology 2004
23. Heintz AP Hacker NF Berek JS Rose TP Munoz AK Lagasse LD Cytoreductive surgery in ovarian carcinoma: feasibility and morbidity Obstet Gynecol 1986 67 783 8